Hanwha and SoftBank could exit the advanced biomaterials developer in the offering, which will follow more than $870m in funding.

US-based advanced materials producer Zymergen has filed for a $100m initial public offering that would provide exits for conglomerate Hanwha and internet and telecommunications group SoftBank. Zymergen is developing technology that can precision-engineer microorganisms to produce biomolecules used in the manufacturing processes of a variety of products across the electronics, personal care and agricultural sectors.…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.